Fingerprint
Dive into the research topics where Hun Ju Lee is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma
Abramson, J. S., Straus, D. J., Bartlett, N. L., Burke, J. M., Lynch, R. C., Domingo Domenech, E., Hess, B., Schuster, S. R., Linhares, Y., Gandhi, M., Shah, H. R., Jurczak, W., Re, A., Hahn, U., Prince, H. M., Guo, W., Davis, G., Ho, L., Fanale, M. & Yasenchak, C. A. & 1 others, , Apr 9 2026, In: Blood. 147, 15, p. 1713-1722 10 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations -
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma
Akkad, N., Feng, L., Westin, J. R., Hagemeister, F. B., Lee, H. J., Fayad, L., Ahmed, S., Nair, R., Rodriguez, M. A., Strati, P., Chihara, D., Flowers, C. R., Claret, L., Ibanez, K., Wang, M., Fowler, N., Henderson, J., Davis, R. E., Neelapu, S. S. & Green, M. & 1 others, , Sep 9 2025, In: Blood Advances. 9, 17, p. 4396-4404 9 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma
Lee, H. J., Ramchandren, R., Friedman, J., Melear, J., Flinn, I. W., Burke, J. M., Linhares, Y., Gonzales, P., Peterson, M., Raval, M., Chintapatla, R., Feldman, T. A., Yimer, H., Islas-Ohlmayer, M., Patel, A., Metheny, L., Dean, A., Rana, V., Gandhi, M. D. & Renshaw, J. & 4 others, , Jan 16 2025, In: Blood. 145, 3, p. 290-299 10 p.Research output: Contribution to journal › Article › peer-review
Open Access14 Link opens in a new tab Scopus citations -
Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results
Cheson, B. D., Bartlett, N. L., Knopf, B., Lee, H. J., Advani, R. H., Christian, B., Diefenbach, C. S., Feldman, T. A. & Ansell, S. M., Aug 12 2025, In: Blood Advances. 9, 15, p. 3750-3753 4 p.Research output: Contribution to journal › Letter › peer-review
Open Access4 Link opens in a new tab Scopus citations -
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma
Mei, M., Palmer, J., Lee, H. J., Isufi, I., Chen, R., Tsai, N. C., Armenian, S., Godfrey, J., Song, J. Y., Baird, J. H., Thiruvengadam, S., Samara, Y., Flores, J., Peters, L., Rosen, S., Kwak, L., Forman, S. J. & Herrera, A. F., May 2025, In: HemaSphere. 9, 5, e70126.Research output: Contribution to journal › Article › peer-review
Open Access6 Link opens in a new tab Scopus citations